Hans Biomed KRX:042520KOSDAQ
한스바이오메드 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days2
DART filings, 7 days0
Articles tracked2since Sep 11
In Q1 2026, Hans Biomed reported revenue of ₩34.5bn, up 42.8% year on year, and operating profit of ₩4.4bn. Hans Biomed (한스바이오메드) appeared in 2 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Sep 11 with 1 article.
Hans Biomed quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q1 2026 | ₩34.5bn | +42.8% | ₩4.4bn | ₩3.7bn |
| Q4 2025 | ₩30.3bn | +52.3% | ₩2.1bn | ₩1.9bn |
| Q3 2025 derived | ₩23.7bn | +21.6% | −₩27.0bn | −₩27.9bn |
| Q2 2025 | ₩22.0bn | +5.9% | ₩41m | −₩3.4bn |
| Q1 2025 | ₩24.2bn | +18.1% | ₩1.8bn | ₩729m |
| Q4 2024 | ₩19.9bn | – | −₩749m | −₩2.0bn |
| Q3 2024 derived | ₩19.5bn | +2.6% | −₩1.1bn | −₩6.2bn |
| Q2 2024 | ₩20.8bn | +12.7% | ₩654m | −₩32m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
Hans Biomed top stories 2 weeks, by number of outlets
- 1
- 2
